BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 22242164)

  • 21. Synthesis and biological evaluation of (6- and 7-phenyl) coumarin derivatives as selective nonsteroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1.
    Starcević S; Brozic P; Turk S; Cesar J; Rizner TL; Gobec S
    J Med Chem; 2011 Jan; 54(1):248-61. PubMed ID: 21138273
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel estrone mimetics with high 17beta-HSD1 inhibitory activity.
    Oster A; Klein T; Werth R; Kruchten P; Bey E; Negri M; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
    Bioorg Med Chem; 2010 May; 18(10):3494-505. PubMed ID: 20413314
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 6-Hydroxybenzothiophene ketones: potent inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) owing to favorable molecule geometry and conformational preorganization.
    Miralinaghi P; Schmitt C; Hartmann RW; Frotscher M; Engel M
    ChemMedChem; 2014 Oct; 9(10):2294-308. PubMed ID: 25044709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacophore modelling of 17beta-HSD1 enzyme based on active inhibitors and enzyme structure.
    Karkola S; Alho-Richmond S; Wahala K
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):225-8. PubMed ID: 18822344
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of a non-estrogenic irreversible inhibitor of 17β-hydroxysteroid dehydrogenase type 1 from 3-substituted-16β-(m-carbamoylbenzyl)-estradiol derivatives.
    Maltais R; Ayan D; Trottier A; Barbeau X; Lagüe P; Bouchard JE; Poirier D
    J Med Chem; 2014 Jan; 57(1):204-22. PubMed ID: 24328103
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of potential preclinical candidates with promising in vitro ADME profile for the inhibition of type 1 and type 2 17β-Hydroxysteroid dehydrogenases: Design, synthesis, and biological evaluation.
    Abdelsamie AS; Salah M; Siebenbürger L; Hamed MM; Börger C; van Koppen CJ; Frotscher M; Hartmann RW
    Eur J Med Chem; 2019 Sep; 178():93-107. PubMed ID: 31176098
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel inhibitors of 17beta-hydroxysteroid dehydrogenase type 1: templates for design.
    Allan GM; Vicker N; Lawrence HR; Tutill HJ; Day JM; Huchet M; Ferrandis E; Reed MJ; Purohit A; Potter BV
    Bioorg Med Chem; 2008 Apr; 16(8):4438-56. PubMed ID: 18329273
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of a biological screening system for the evaluation of highly active and selective 17beta-HSD1-inhibitors as potential therapeutic agents.
    Kruchten P; Werth R; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):154-7. PubMed ID: 18984028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New drug-like hydroxyphenylnaphthol steroidomimetics as potent and selective 17β-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of estrogen-dependent diseases.
    Marchais-Oberwinkler S; Wetzel M; Ziegler E; Kruchten P; Werth R; Henn C; Hartmann RW; Frotscher M
    J Med Chem; 2011 Jan; 54(2):534-47. PubMed ID: 21189020
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of highly potent, nonsteroidal 17β-hydroxysteroid dehydrogenase type 1 inhibitors by virtual high-throughput screening.
    Starčević Š; Turk S; Brus B; Cesar J; Lanišnik Rižner T; Gobec S
    J Steroid Biochem Mol Biol; 2011 Nov; 127(3-5):255-61. PubMed ID: 21920439
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis of 16β-derivatives of 3-(2-bromoethyl)-estra-1,3,5(10)-trien-17β-ol as inhibitors of 17β-HSD1 and/or steroid sulfatase for the treatment of estrogen-dependent diseases.
    Lespérance M; Roy J; Djiemeny Ngueta A; Maltais R; Poirier D
    Steroids; 2021 Aug; 172():108856. PubMed ID: 33945801
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First Structure-Activity Relationship of 17β-Hydroxysteroid Dehydrogenase Type 14 Nonsteroidal Inhibitors and Crystal Structures in Complex with the Enzyme.
    Braun F; Bertoletti N; Möller G; Adamski J; Steinmetzer T; Salah M; Abdelsamie AS; van Koppen CJ; Heine A; Klebe G; Marchais-Oberwinkler S
    J Med Chem; 2016 Dec; 59(23):10719-10737. PubMed ID: 27933965
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estrone C15 derivatives--a new class of 17beta-hydroxysteroid dehydrogenase type 1 inhibitors.
    Messinger J; Husen B; Koskimies P; Hirvelä L; Kallio L; Saarenketo P; Thole H
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):216-24. PubMed ID: 19014997
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Probing the origins of 17β-hydroxysteroid dehydrogenase type 1 inhibitory activity via QSAR and molecular docking.
    Srungboonmee K; Songtawee N; Monnor T; Prachayasittikul V; Nantasenamat C
    Eur J Med Chem; 2015; 96():231-7. PubMed ID: 25884113
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The regulation and inhibition of 17beta-hydroxysteroid dehydrogenase in breast cancer.
    Purohit A; Tutill HJ; Day JM; Chander SK; Lawrence HR; Allan GM; Fischer DS; Vicker N; Newman SP; Potter BV; Reed MJ
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):199-203. PubMed ID: 16414180
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of a new class of bicyclic substituted hydroxyphenylmethanones as 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) inhibitors for the treatment of osteoporosis.
    Wetzel M; Gargano EM; Hinsberger S; Marchais-Oberwinkler S; Hartmann RW
    Eur J Med Chem; 2012 Jan; 47(1):1-17. PubMed ID: 21945251
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of the heterocycle in bis(hydroxyphenyl)triazoles for inhibition of 17beta-Hydroxysteroid Dehydrogenase (17beta-HSD) type 1 and type 2.
    Al-Soud YA; Bey E; Oster A; Marchais-Oberwinkler S; Werth R; Kruchten P; Frotscher M; Hartmann RW
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):212-5. PubMed ID: 18848601
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of structural modifications at positions 13, 16 and 17 of 16β-(m-carbamoylbenzyl)-estradiol on 17β-hydroxysteroid dehydrogenase type 1 inhibition and estrogenic activity.
    Maltais R; Trottier A; Barbeau X; Lagüe P; Perreault M; Thériault JF; Lin SX; Poirier D
    J Steroid Biochem Mol Biol; 2016 Jul; 161():24-35. PubMed ID: 26519987
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 17beta-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer.
    Day JM; Foster PA; Tutill HJ; Parsons MF; Newman SP; Chander SK; Allan GM; Lawrence HR; Vicker N; Potter BV; Reed MJ; Purohit A
    Int J Cancer; 2008 May; 122(9):1931-40. PubMed ID: 18183589
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis of substituted 15β-alkoxy estrone derivatives and their cofactor-dependent inhibitory effect on 17β-HSD1.
    Herman BE; Kiss A; Wölfling J; Mernyák E; Szécsi M; Schneider G
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1271-1286. PubMed ID: 31307240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.